title: Unexpected prolonged myelosuppression after mitomycin, mitoxantrone and methotrexate.
abstract: 28 patients (26 with breast cancer and 2 with colon cancer) received mitomycin, mitoxantrone and methotrexate (MMM). Half the patients had grade III-IV leukopenia and 29% had grade III-IV thrombocytopenia. The median time of recovery to WHO grade 0 was 62 and 128 days, respectively. Thrombocytopenia and leukopenia were more frequent and longer lasting after the three-drug part of the therapy, which suggests a critical role for mitomycin in this toxicity.
authors.affiliation: Department of Radiotherapy and Oncology, Helsinki University Central Hospital, Finland.
authors.forename: T T
authors.initials: TT
authors.lastname: Muhonen
authors.forename: T A
authors.initials: TA
authors.lastname: Wiklund
authors.forename: C P
authors.initials: CP
authors.lastname: Blomqvist
authors.forename: S O
authors.initials: SO
authors.lastname: Pyrhönen
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D001943:Breast Neoplasms / Q000188:drug therapy; D003110:Colonic Neoplasms / Q000188:drug therapy; D005260:Female; D006801:Humans; D007970:Leukopenia / Q000139:chemically induced*; D008297:Male; D008727:Methotrexate / Q000009:adverse effects; D008875:Middle Aged; D008937:Mitomycins / Q000009:adverse effects; D008942:Mitoxantrone / Q000009:adverse effects; D013921:Thrombocytopenia / Q000139:chemically induced*; D013997:Time Factors
chemical_list: D008937:Mitomycins; D008942:Mitoxantrone; D008727:Methotrexate